Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Vania T.M. Hungria, Hans C. Lee, Rafat Abonour, Robert M. Rifkin, Evangelos Terpos, Xavier Leleu, Caitlin L. Costello, Frits van Rhee, Katja C. Weisel, Noemi Puig, Jesus G. Berdeja, Gordon Cook, Saad Z. Usmani, Michael A. Thompson, Mario Boccadoro, Jeffrey A. Zonder, Andrew Spencer, Roman Hajek, Suzanne R. Fanning, Kevin Boyd, Jim Omel, Mira Armour, Kathryn E. Morgan, Ronak S. Patel, Gary L. Carlson, Renda H. Ferrari, Dawn Marie Stull, Kaili Ren, Dasha Cherepanov, James V. Pottala, Ajai Chari
Institutions: São Germano Oncologia, The University of Texas MD Anderson Cancer Center, Indiana University School of Medicine, Rocky Mountain Cancer Centers, National and Kapodistrian University of Athens, Centre Hospitalier Universitaire de Poitiers, University of California San Diego, Moores Cancer Center, University of Arkansas for Medical Sciences, University Medical Center Hamburg-Eppendorf, Instituto de Investigación Biomédica de Salamanca, Tennessee Oncology, Leeds Teaching Hospitals NHS Trust, National Institute for Health and Care Research, Levine Cancer Institute, Aurora Health Care, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Wayne State University, The Barbara Ann Karmanos Cancer Institute, The Alfred Hospital, Alfred Health, Monash University, University of Ostrava, University Hospital Ostrava, Prisma Health, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Takeda Oncology (United States), Pharmaceutical Product Development (United States), Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2985338189